These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 31340438)

  • 21. Immunomodulatory effects of ablation therapy on tumors: Potentials for combination with immunotherapy.
    Qian L; Shen Y; Xie J; Meng Z
    Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188385. PubMed ID: 32554098
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment].
    Duruisseaux M; Lize-Dufranc C; Badoual C; Bibeau F
    Ann Pathol; 2017 Feb; 37(1):46-54. PubMed ID: 28131419
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy.
    Wang Y; Ma R; Liu F; Lee SA; Zhang L
    Front Immunol; 2018; 9():374. PubMed ID: 29556232
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predicting immunotherapy response through genomics.
    Cormedi MCV; Van Allen EM; Colli LM
    Curr Opin Genet Dev; 2021 Feb; 66():1-9. PubMed ID: 33307238
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy.
    Ciardiello D; Vitiello PP; Cardone C; Martini G; Troiani T; Martinelli E; Ciardiello F
    Cancer Treat Rev; 2019 Jun; 76():22-32. PubMed ID: 31079031
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting the tumor microenvironment and T cell metabolism for effective cancer immunotherapy.
    Hope HC; Salmond RJ
    Eur J Immunol; 2019 Aug; 49(8):1147-1152. PubMed ID: 31270810
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical Challenges of Immune Checkpoint Inhibitors.
    de Miguel M; Calvo E
    Cancer Cell; 2020 Sep; 38(3):326-333. PubMed ID: 32750319
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dissecting the mechanisms of immune checkpoint therapy.
    Sharma P; Allison JP
    Nat Rev Immunol; 2020 Feb; 20(2):75-76. PubMed ID: 31925406
    [No Abstract]   [Full Text] [Related]  

  • 30. Cancer immunotherapy of patients with HIV infection.
    Gonzalez-Cao M; Martinez-Picado J; Karachaliou N; Rosell R; Meyerhans A
    Clin Transl Oncol; 2019 Jun; 21(6):713-720. PubMed ID: 30446984
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Editorial: Immune Checkpoint Molecules and Cancer Immunotherapy.
    Bazhin AV; Amedei A; Karakhanova S
    Front Immunol; 2018; 9():2878. PubMed ID: 30568661
    [No Abstract]   [Full Text] [Related]  

  • 32. Towards In Silico Prediction of the Immune-Checkpoint Blockade Response.
    Chen K; Ye H; Lu XJ; Sun B; Liu Q
    Trends Pharmacol Sci; 2017 Dec; 38(12):1041-1051. PubMed ID: 29089139
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Masterful Antibodies: Checkpoint Blockade.
    Lonberg N; Korman AJ
    Cancer Immunol Res; 2017 Apr; 5(4):275-281. PubMed ID: 28373215
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune Checkpoint Inhibitor Therapy in Breast Cancer.
    Santa-Maria CA; Nanda R
    J Natl Compr Canc Netw; 2018 Oct; 16(10):1259-1268. PubMed ID: 30323094
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of immune-checkpoint inhibitors in lung cancer.
    Jain P; Jain C; Velcheti V
    Ther Adv Respir Dis; 2018; 12():1753465817750075. PubMed ID: 29385894
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting Multiple Receptors to Increase Checkpoint Blockade Efficacy.
    Zahavi DJ; Weiner LM
    Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30621125
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunotherapy in colorectal cancer: Available clinical evidence, challenges and novel approaches.
    Tintelnot J; Stein A
    World J Gastroenterol; 2019 Aug; 25(29):3920-3928. PubMed ID: 31413527
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunotherapy of Colon Cancer.
    Stein A; Folprecht G
    Oncol Res Treat; 2018; 41(5):282-285. PubMed ID: 29705788
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combining Radiotherapy and Immunotherapy in Lung Cancer: Can We Expect Limitations Due to Altered Normal Tissue Toxicity?
    Wirsdörfer F; de Leve S; Jendrossek V
    Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30577587
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The "immune checkpoints", how does it work].
    Granier C; Soumelis V; Mandavit M; Gibault L; Belazzoug R; de Guillebon E; Badoual C; Tartour E; Roussel H
    Ann Pathol; 2017 Feb; 37(1):18-28. PubMed ID: 28160999
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.